Investing News NetworkYour trusted source for investing success

Videos
Companies
Press Releases
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Private Placements
Trending
Trending Articles

How Would a New BRICS Currency Affect the US Dollar? (Updated 2025)

13 Canadian Crypto ETFs (Updated 2025)

10 Top Oil-producing Countries

Could the Silver Price Really Hit $100 per Ounce?

Mali Enforces Gold Seizure at Barrick's Loulo-Gounkoto Mine

Uranium Stocks: 5 Biggest Companies

How Could Trump's US Election Win Affect the Gold Price?

A State-by-State Guide to Cannabis in Australia

Rare Earths Stocks: 9 Biggest Companies

Trending Press Releases

European Lithium Limited (ASX: EUR) – Trading Halt

Spearmint More Than Doubles its Crypto Exposure

Flynn Expands Key Gold Targets at Golden Ridge, NE Tasmania

Skyharbour to Carry Out Multi-Phased, 2025 Drilling Campaign Totalling 16-18,000 Metres at its Russell Lake and Moore Uranium Projects, Saskatchewan

Pilot Plant Downstream Process Produces Lithium Carbonate with 99.78% Purity

More Press Releases
Trending Companies

Skyharbour Resources

SYH:CA

Freegold Ventures

FVL:CA

Rua Gold

RUA:CC

First Helium

HELI:CA
More Companies
Trending Reports

2025 Lithium Market Outlook

2025 Copper Outlook Report

2025 Oil & Gas Outlook Report

2025 Uranium Outlook

More Outlook Reports
Resource
Resource
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Tech
Tech
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Life Science
Life Science
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Gold Price
Silver Price
Copper Price
Oil Price
Uranium
Artificial Intelligence
loader

Corvus Pharmaceuticals

NASDAQ:CRVS

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the most critical cellular elements of the immune system.

Press Releases

Corvus Presents Updated Biomarker and Clinical Results from Lead Pipeline Programs

Corvus Announces Presentation of Preclinical Data on CPI-818, a First-in-class Covalent Inhibitor of ITK Targeting T-Cell Lymphomas

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the most critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers and autoimmune diseases. The company's lead product candidate is CPI-006 which is a potent humanized monoclonal antibody that is designed to react with a specific site on CD73. Its other product candidates are CPI-818, CPI-935, CPI-182 and Ciforadenant.

Interactive Chart

×